Impact of renal dysfunction on immediate versus staged revascularization of non-culprit lesions in patients with ST segment elevation myocardial infarction: a pre-specified subgroup analysis of the randomized MULTISTARS AMI trial
Clinical Research in Cardiology · 2026
DOI: 10.1007/s00392-026-02875-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von Miklos Rohla und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction, Coronary Artery Disease, Renal Insufficiency. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
Background
Renal dysfunction might affect outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) undergoing percutaneous coronary intervention (PCI).
Methods
In MULTISTARS AMI, patients with STEMI and MVD were randomized to immediate or staged PCI of non-culprit lesions. In this pre-specified analysis, patients were stratified according to the presence of renal dysfunction at baseline, defined at an estimated glomerular filtration rate (eGFR) of 60 ml/min/1.73 m 2 . Patients with an eGFR < 30 ml/min/1.73 m 2 were excluded from the trial. The primary endpoint was a composite of death, non-fatal myocardial infarction, stroke, unplanned revascularization, or hospitalization for heart failure at 1 year.
Results
In MULTISTARS AMI, 108 (13%) of 832 patients had renal dysfunction. The primary endpoint occurred more frequently in patients with renal dysfunction (19.4% vs. 11.2%, unadjusted HR 1.82, 95% CI 1.13–2.94), primarily driven by higher rates of death. Among patients with renal dysfunction, the rates of the primary end point were 14.5% and 24.5% in the immediate and staged PCI groups (unadjusted HR 0.55, 95% CI 0.23–1.33). There was no interaction between renal dysfunction and the randomized treatment assignment with respect to the primary end point (adjusted HR 1.30, 95% CI 0.8–2.20, p int 0.82). The occurrence of acute renal insufficiency was statistically similar in patients with renal dysfunction who underwent immediate and staged PCI (10.9% vs. 18.9%, unadjusted HR 0.61, 95% CI 0.22–1.72, p int 0.09). Renal dysfunction at baseline emerged as a strong risk factor for the development of acute renal insufficiency (adjusted HR 5.0, 95% CI 2.30–10.70, p < 0.01).
Conclusions
Outcomes with immediate compared to staged multivessel PCI did not appear significantly altered by the presence of renal dysfunction at baseline. (Supported by Boston Scientific; MULTISTARS AMI ClinicalTrials.gov number, NCT03135275).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.
- Austrian Heart Foundation, Vienna, Austria.
- Medical Private University Burgenland (GmbH), Pinkafeld, Austria.
- Interventional Cardiology Unit, Degli Infermi Hospital, Rivoli, Turin, Italy.
- Department of Internal Medicine and Cardiology, Technische Universität Dresden, University Clinic, Herzzentrum Dresden, Dresden, Germany.
- Heart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital for the Universities of Kiel, Lübeck and Hamburg, Bad Segeberg, Germany.
Förderung
- Boston Scientific Corporation
Zitieren
APA
Rohla, M., Huber, K., Varbella, F., Linke, A., Schwarz, B., Felix, S. B., Seiffert, M., Kesterke, R., Nordbeck, P., Witzenbichler, B., Lang, I. M., Kessler, M., Valina, C., Dibra, A., Jakob, P., Moccetti, M., Vercellino, M., Gaede, L., Bott-Flügel, L., …, & MULTISTARS AMI Investigators (2026). Impact of renal dysfunction on immediate versus staged revascularization of non-culprit lesions in patients with ST segment elevation myocardial infarction: a pre-specified subgroup analysis of the randomized MULTISTARS AMI trial. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-02875-w
Vancouver
Rohla M, Huber K, Varbella F, Linke A, Schwarz B, Felix SB, et al. Impact of renal dysfunction on immediate versus staged revascularization of non-culprit lesions in patients with ST segment elevation myocardial infarction: a pre-specified subgroup analysis of the randomized MULTISTARS AMI trial. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-02875-w
BibTeX
@article{Rohla2026,
author = {Rohla, Miklos and Huber, Kurt and Varbella, Ferdinando and Linke, Axel and Schwarz, Bettina and Felix, Stephan B and Seiffert, Moritz and Kesterke, Rahel and Nordbeck, Peter and Witzenbichler, Bernhard and Lang, Irene M and Kessler, Mirjam and Valina, Christian and Dibra, Alban and Jakob, Philipp and Moccetti, Marco and Vercellino, Matteo and Gaede, Luise and Bott-Flügel, Lorenz and Stehli, Julia and Candreva, Alessandro and Paneni, Francesco and Templin, Christian and Schindler, Matthias and Wischnewsky, Manfred and Zanda, Greca and Quadri, Giorgio and Mangner, Norman and Toma, Aurel and Magnani, Giulia and Clemmensen, Peter and Lüscher, Thomas F and Münzel, Thomas and Schulze, P Christian and Laugitz, Karl-Ludwig and Rottbauer, Wolfgang and Neumann, Franz-Josef and Schneider, Steffen and Riemer, Thomas and Weidinger, Franz and Achenbach, Stephan and Richardt, Gert and Kastrati, Adnan and Ford, Ian and Ruschitzka, Frank and Stähli, Barbara E and MULTISTARS AMI Investigators, MULTISTARS AMI Investigators},
title = {Impact of renal dysfunction on immediate versus staged revascularization of non-culprit lesions in patients with ST segment elevation myocardial infarction: a pre-specified subgroup analysis of the randomized MULTISTARS AMI trial},
journal = {Clinical Research in Cardiology},
year = {2026},
doi = {10.1007/s00392-026-02875-w}
}
EUVIMED